Patent application number | Description | Published |
20080219981 | Diagnostic Kit for Solid Cancer and Medicament for Solid Cancer Therapy - The present invention provides novel solid cancer antigenic proteins, and diagnostic kits for solid cancer and therapeutic agents for solid cancer based on the antigenic proteins. Specifically, the present invention provides a human solid cancer antigenic polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 48, 50, 52, 54, 56, 59, 61, 63, 65, 67, 69, 71, 73, and 75. | 09-11-2008 |
20080227705 | Apoptosis-inducing agent and method for inducing apoptosis - An object of the present invention is to provide a novel means for stably and surely inducing cell apoptosis using the c-myc gene as a target. The present invention relates to an apoptosis-inducing agent containing a protein that interacts with an FBP protein or a polynucleotide encoding the protein as an active ingredient and a method for inducing apoptosis, which comprises a step of causing the apoptosis-inducing agent to come into contact with cells. | 09-18-2008 |
20090004682 | Method for Measuring Glucose Concentration in Blood Using Infrared Spectroscopy and Instrument Employing It - The objective of the present invention is to provide a method and instrument for measuring glucose concentration in blood using infrared spectroscopy. Glucose concentration in blood is measured based on an integrated value obtained by measuring an absorption spectrum that includes the wavelength range of 1020-1040 cm | 01-01-2009 |
20090275059 | Marker proteins for diagnosing liver disease and method of diagnosing liver disease using the same - Using the protein chip technology, biological samples such as sera are subjected to proteome analysis. Thus, a protein which is a human fibrinogen α-E chain decomposition product and has a molecular weight of 5,900, a protein which is an apolipoprotein AII decomposition product and has a molecular weight of 7,800, and a protein which is an apolipoprotein AI decomposition product and has a molecular weight of 28,000, each showing an increase or a decrease with the habit of drinking, are newly found out. By detecting or quantifying these proteins, a liver disease in a subject such as one having a problem of drinking can be diagnosed at the early stage. | 11-05-2009 |
20100196928 | Gene specific to cancer and diagnosis kit using the same - The present invention provides a new additional identification of a gene related to cancer expression and a diagnostic kit using the same. | 08-05-2010 |
20110108722 | Novel Biomarkers Of Biliary Tract Cancer - A method of detecting an abnormal amount of a biomarker associated with biliary tract cancer in a subject can comprise: a) quantitating an amount of a fragment of prothrombin having an m/z value of about 4204 m/z in a biological sample from the subject; and b) comparing the quantitated value obtained in (a) with a threshold value. | 05-12-2011 |
20120276562 | 5.9 kDa PEPTIDE IMMUNOASSAY METHOD - Disclosed is an immunoassay method whereby a 5.9 kDa peptide which results from the degradation of the α-E chain and α chain of human fibrinogens and which is used as a peptide marker for diagnosing hepatic disease can be specifically assayed in a biological sample containing contaminating peptides by bringing antibodies that recognize the N terminal of said peptide marker and antibodies that recognize the C terminal of said peptide marker into contact with said peptide marker, forming immune complexes of said peptide marker and the two antibodies, and immunoassaying the obtained immune complexes. | 11-01-2012 |
20120282638 | METHOD FOR IMMUNOASSAY OF AUTOANTIBODY AGAINST KU86, KIT FOR USE IN SAME, AND METHOD FOR DETERMINATION OF PRIMARY HEPATOCELLULAR CARCINOMA USING SAME - An autoantibody against Ku86 can be measured by reacting the autoantibody contained in a sample with a Ku86 antigen (which serves as a reagent) to produce an immune complex of the autoantibody and the Ku86 antigen and measuring the immune complex using a labeled anti-human immunoglobulin antibody. The measurement of the autoantibody enables the determination of primary hepatocellular carcinoma. | 11-08-2012 |
20120309034 | METHOD FOR MEASURING IMMUNITY OF COMPLEX OF Ku86 AND AUTOANTIBODY THEREOF, KIT USED THEREFOR, AND METHOD FOR DETERMINING CANCER USING SAME - A reaginic antibody of Ku86 and a substance capable of binding with the autoantibody of Ku86 are acted on a complex of Ku86 and the autoantibody thereof in a subject. Said complex can be measured by measuring the obtained immune complex of the aforementioned complex, reaginic antibody, and substance capable of binding with the autoantibody of Ku86. As a consequence, it is possible to determine whether the cancer is a primary hepatoma, colon cancer, stomach cancer, pancreatic cancer, breast cancer, lung cancer, or an esophageal cancer. | 12-06-2012 |
20130089871 | MARKER FOR DETECTION AND/OR DISCRIMINATION OF NON-ALCOHOLIC STEATOHEPATITIS, METHOD FOR DETECTION AND/OR DISCRIMINATION OF NON-ALCOHOLIC STEATOHEPATITIS, AND KIT FOR USE IN THE METHOD - The detection of a non-alcoholic steatohepatitis patient and the accurate discrimination between a normal person and a non-alcoholic steatohepatitis patient can be achieved by measuring alanine-glyoxylate amino transferase in a sample. | 04-11-2013 |